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INTRODUCTION
Non-small cell lung cancer (NSCLC) represents both a bio-
logically and histopathologically heterogenous group of tu-
mors. Although complete surgical resection is the only cura-
tive therapy for NSCLC patients, the survival rate, even of
patients with early stage NSCLC, is not satisfactory. This has
led to a search for prognostic parameters of lung cancer from
clinical data or histological examination. Recently, the poten-
tial prognostic roles of cancer cell proliferation and molecu-
lar biological alterations in oncogenes and tumor suppressor
genes have been investigated in NSCLC, but none has been
found to yield unambiguous results (1). 
Epidermal growth factor receptor (EGFR) is a 170 kDa
transmembrane glycoprotein with an intracellular domain
that exhibits tyrosine kinase activity. EGFR is involved in
cellular proliferation and differentiation (2, 3), and overexpres-
sion of mRNA and/or protein encoded by the EGFR gene has
been observed in many types of human malignancies, includ-
ing breast, gastric, colorectal, and bladder cancer, as well as
in 30% to 70% of NSCLCs (4-8). Findings have suggested
that assays of EGFR mRNA and/or protein may be useful
for predicting the prognosis of tumors. For example, enhanced
expression of EGFR has been related to poorer prognosis in
breast cancer, and advanced gastric carcinomas have shown
a higher level of EGFR expression than early gastric carcino-
mas (4, 6, 9, 10). Although some studies have reported an
association between enhanced EGFR expression and poor
prognosis in patients with lung cancer, the prognostic role
of EGFR remains yet controversial (11-14). 
In the present study, we assayed immunohistochemically
EGFR expression in human NSCLC tissues, and we analyzed
the relationships between EGFR expression and several pro-
gnostic variables, including angiogenesis and tumor cell pro-
liferation. Furthermore, we investigated the prognostic role
of EGFR overexpression in relation to disease-free survival
and overall survival.
MATERIALS AND METHODS
Study population
From February 1991 to March 1996, ninety-four patients
with stage II or IIIA NSCLC underwent curative resection
and received 2 courses of adjuvant MVP [mitomycin C (8
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Epidermal Growth Factor Receptor (EGFR) Expression in Operable
Non-small Cell Lung Carcinoma
This study was performed to assay the expression of epidermal growth factor recep-
tor (EGFR) in non-small cell lung carcinoma (NSCLC), and to investigate the rela-
tionship between EGFR status and various clinicopathologic features of NSCLC,
including angiogenesis and proliferative activity. The expression of EGFR, microves-
sel count (MVC) measured by CD31 monoclonal antibody, and proliferative activity
using Ki-67 labeling index were immunohistochemically analyzed in formalin-fixed
and paraffin-embedded tissue specimens from 65 patients with completely resected
stage II-IIIA NSCLC. Pathologic and clinical records of all patients were retrospec-
tively reviewed. EGFR was expressed in 18 (28%) of 65 NSCLC samples. More
squamous tumors (35%) were EGFR-positive than other NSCLCs (23%) (p-value
0.308). There was a statistically significant correlation between EGFR expression
and Ki-67 labeling index (p-value 0.042), but no correlation was observed between
EGFR expression and tumor histology, stage, or MVC. There were no differences
between EGFR positive and negative tumors in 5-yr disease-free survival (60% vs.
52%, p-value 0.5566) and 5-yr overall survival (53% vs. 45%, p-value 0.3382) rates.
In conclusion, our findings suggest that NSCLC proliferative activity may be depen-
dent on EGFR expression, but that EGFR expression had no significant impact on
survival in curatively resected NSCLC. 
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mg/m2), vinblastine (8 mg/m2), and cisplatin (60 mg/m2)]
chemotherapy, followed by sequential radiotherapy (50 Gy)
3 weeks later. This protocol has shown relatively low recur-
rence and improved overall survival rates in patients with stage
II and IIIA NSCLC (15). We obtained 65 of these resected
lung tumor tissue samples from the pathology department
for this study. We also reviewed the medical records and pa-
thology data of these patients in order to determine their clini-
copathologic variables, including age, sex, TNM stage, and
histologic grade and types of tumors, as well as their disease
free survival and overall survival. 
Immunohistochemical method 
Paraffin-embedded blocks were sectioned at about 4- m
thickness, and deparaffinized and rehydrated through a graded
alcohol series. The slides were pretreated in the microwave
with citrate buffer (pH 6.0) at 90℃ for 10 min to retrieve
antigen, immersed in 0.3% hydrogen peroxide for 20 min
to block endogenous peroxidase activity, washed, and incu-
bated overnight at 4℃ with normal bovine serum to reduce
nonspecific antibody binding. Subsequently, all tissue sections
were incubated with mouse monoclonal antibody to EGFR
(1:50; Novocastra Laboratories, Newcastle, U.K.) and CD31,
a sensitive marker for endothelial cells (16) (JC70, 1:50; DA-
KO, Denmark), and with rabbit polyclonal antibody to Ki-67
protein, a marker for tumor cell proliferation (1:100; DAKO,
Denmark). The slides were subsequently incubated with bio-
tinylated goat anti-mouse antibody, and then with peroxidase-
conjugated streptavidin (DAKO LSAB+ kit; Dako Corp.,
Carpinteria, CA, U.S.A.). Reaction products were subjected
to a color reaction with 3,3-diaminobenzidine tetrahydrochlo-
ride containing 3% H2O2 in Tris buffer and were lightly coun-
terstained with Mayer’s hematoxylin. 
Evaluation of the immunohistochemical staining
All slides were coded and evaluated by an experienced pa-
thologist who had no knowledge of the patients’ identity or
clinical status. EGFR assessment was based on cytoplasmic
staining intensity was, which was scored as 0 (negative, <5%
of cells stained), 1+(weak, 5-20% of cells stained), 2+(mod-
erate, 20-50% of cells stained), and 3+(strong, >50% of cells
stained). Only tumors exhibiting 2+~3+ staining were con-
sidered positive for EGFR expression (17). 
For microvessel count (MVC) assessment, each slide was
first scanned by light microscopy at ×100 magnification to
determine three ‘‘hot spots’’ defined as areas with the maxi-
mum number of microvessels. The slides were then examined
at×200 magnification, and three ×200 fields in each ‘‘hot
spot’’ were evaluated by counting the number of positive cells.
The highest number was recorded for statistical analysis. MVC
values were expressed as mean±standard deviation (SD) (18).
Ki-67-positive cells were evaluated by nuclear staining,
with the number of positive cells in 1000 tumor cells count-
ed at high magnification (×400). The Ki-67 labeling index
was calculated as positive nuclei ×100/total number of count-
ed nuclei (%). For statistical analysis, a threshold value of 15%
Ki-67 positive tumor cells were defined as separating tumors
with a high proliferation rate from those with a low prolifera-
tion rate (19).
Statistical analysis
Using the SPSS 11.0 program, the relationships of EGFR
expression to clinicopathologic variables, MVC, and Ki-67-
based proliferative activity were analyzed by chi-square or
Fisher’s exact test. The significance of MVC for each clinico-
pathologic factor, including EGFR expression, was evaluated
using Student’s t test. Univariate analysis was performed to
identify prognostic factors for survival by modeling Kaplan-
Meier survival curves, and the difference in survival curves
was compared by the log-rank test. Multivariate analysis was
performed by Cox’ proportional hazards regression model.
Disease-free survival (DFS) was defined as the time from the
date of operation to a documented recurrence or death from
any other cause. Overall survival (OS) was defined as the time
from the date of operation to death or last follow-up. In all
statistical analyses, the difference was considered to be signif-
icant when the p-value was less than 0.05.
RESULTS
Patient characteristics and EGFR expression in 65 NSCLC
Sixty-five NSCLC patients (51 males and 14 females), with
a median age of 58 yr (range, 34-73 yr) were studied. Of the
65 patients, 26 had squamous cell carcinoma, 29 had adeno-
carcinoma, 2 had bronchioloalveolar carcinoma, and 8 had
adenosquamous carcinoma. Thirty-three cases were stage II
and 32 were stage IIIA. The median follow-up in 33 living
patients was 85.3 months (range, 18-133 months). Table 1
shows patients’ characteristics and relationship with EGFR
expression.
Typical immunostaining patterns for EGFR in NSCLC are
shown in Fig. 1. Immunoreactivity was limited to cancer
cells, and there was very little or no specific staining in the
surrounding stroma. Staining for EGFR was strong in 11/65
(17%), moderate in 7/65 (11%), weak in 25/65 (38%), and
negative in 22/65 (34%) tumor samples. Thus, 18/65 (28%)
NSCLC tissues were positive for EGFR expression. Of the 26
squamous tumors, 9 (35%) were stained moderately or strong-
ly, while of the 39 non-squamous tumors, 9 (23%) were pos-
itive for EGFR. Overall, more squamous tumors were EGFR-
positive than other NSCLCs, but the difference was not sta-
tistically significant.
MVC, as an indicator of neovascularization in primary tu-Expression of EGFR in Non-small Cell Lung Carcinoma 531
mors, was measured by immunohistochemical staining of
endothelial vessels with an anti-CD31 monoclonal antibody.
The 65 tumors assayed had a median MVC of 95.0 per 200×
field (range, 38-209). MVC was significantly associated with
histologic grade but not with any other clinicopathological
or biological variable analyzed (data not shown). 
We found no significant association between EGFR expres-
sion and any clinicopathological parameters, including age,
tumor size, pathologic stage, nodal status, histological type,
and tumor angiogenesis (Table 1).
EGFR expression and proliferative activity 
The proliferative activity of tumors was evaluated by Ki-67
expression. The mean Ki-67 labeling index was 13% (range
0-56%). We divided tumors into groups with low Ki-67 ex-
pression (Ki-67 labeling index <15%) and high Ki-67 expres-
sion (Ki-67 labeling index ≥15%). A high Ki-67 labeling
index was found in 25/61 (40%) tumors. We observed a pos-
itive correlation between EGFR expression and high rate of
tumor proliferation (Table 2). EGFR expression was more fre-
quently detected in the group with high Ki-67 expression
than in the group with low Ki-67 expression (61.1% vs. 38.9
%, p-value 0.042). 
Clinicopathologic
features
No. of
cases
p-value
EGFR expression
Negative (%) Positive (%)
Age (yr)
Age <58 28 21 (75) 7 (25) 0.783
Age≥58 37 26 (70) 11 (30)
Sex
Male 51 37 (73) 14 (27) 0.589
Female 14 10 (71) 4 (29)
Smoking
Smoker* 45 34 (75) 11 (25) 0.411
Non-smoker 16 11 (69) 5 (31)
Stage
II 33 23 (70) 10 (30) 0.783
IIIA 32 24 (75) 8 (25)
Pathologic T stage
1-2 55 40 (72) 15 (27) 0.565
3-4 10 7 (70) 3 (30)
Pathologic N stage
0 6 5 (83) 1 (17) 0.674
1 31 21 (67) 10 (33)
2 28 21 (75) 7 (25)
Histologic type
Squamous 26 17 (65) 9 (35) 0.308
Adenocarcinoma 29 21 (72) 8 (28)
Bronchioloalveolar 2 2 (100) 0 (0) 
Adenosquamous 8 7 (88) 1 (12)
Histologic grade
�
1 or 2 37 24 (65) 13 (35) 0.538
3 16 12 (75) 4 (25)
Total 65 47 (72) 18 (28)
Table 1. Clinical characteristics and relationship with EGFR ex-
pression 
*Smokers include both ex-smoker and current smoker. 
� 1, well differen-
tiated; 2, moderately differentiated; 3, poorly differentiated.
EGFR
expression
No. of 
cases
p-value
Ki-67 labeling index
<15% ≥15% 
Positive 18 7 (38.9%) 11 (61.1%) 0.042
Negative 47 29 (61.7%) 14 (38.3%)
Table 2. Correlation between EGFR expression and proliferative
activity
Fig. 1. Microphotograph showing EGFR immunostaining in NSCLC tissue specimens. Positive immunoreactivity is evident in the neoplas-
tic cells (A), whereas negative immunoreactivity is shown in (B) (×100).
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Survival 
The prognostic impact of clinicopathological variables on
patient survival was evaluated by univariate analysis. Advanced
tumor stage, non-squamous histologic type, high grade tu-
mors, and high level of MVC were significantly associated
with lower DFS (Table 3). EGFR expression alone, however,
could not be correlated with DFS (5-yr DFS, 45% vs. 48%,
p-value 0.8010) or OS (5-yr OS, 48% vs. 44%, p-value 0.4110)
(Fig. 2). By multivariate analysis, only tumor stage, but not
histology, histologic grade, MVC level, or EGFR expression,
had a significant prognostic impact on DFS and OS (Table 4).
DISCUSSION
EGFR expression is frequently detected in many types of
tumors, including the majority of NSCLC. In our study, EGFR
expression was immunohistochemically evaluated in 65 for-
malin-fixed and paraffin-embedded human NSCLC tissues,
and 18 (28%) were positive for EGFR. In previous studies
by other investigators, EGFR was expressed in 30-70% of
Factors SE* p-value HR (95% CI)
�
Stage 0.517 0.009 3.867 (1.405-10.643)
(II vs. IIIA)
Histology 0.496 0.060 0.394 (0.149-1.041)
(squamous vs. 
non-squamous)
Histologic grade
� 0.443 0.061 2.296 (0.964-5.470)
(1 or 2 vs. 3)
EGFR expression 0.520 0.636 0.782 (0.282-2.168)
(negative vs. positive)
Microvessel count 0.551 0.875 0.875 (0.297-2.578)
(<95 vs. ≥95)
Ki-67 labeling index 0.436 0.333 0.656 (0.279~1.541)
(<15% vs. ≥15%)
Table 4. Multivariate analysis of prognostic factors that influence
the 5-yr overall survival
*Standard error. 
� Hazard ratio (95% confidence interval). 
� 1, well differ-
entiated; 2, moderately differentiated; 3, poorly differentiated.
Variables 5-DFS* (%) p-value 5-OS (%) p-value
Age (yr)
Age <58 52.4 0.7257 59.9 0.1827
Age ≥58 54.6 44.2
Sex
Male 52.3 0.8176 47.8 0.0956
Female 57.1 63.9
Stage
II 75.8 0.0004 62.1 0.0275
IIIA 31.1 39.8
Pathologic T stage
1-2 52.8 0.9390 48.2 0.2534
3-4 58.3 67.5
Pathologic N stage
Negative 55.6 0.6911 50.0 0.8540
Positive 53.7 51.3
Histologic type
Squamous 75.0 0.0296 53.0 0.9563
Non-squamous 41.6 50.5
Histologic grade
�
1 or 2 67.9 0.0044 66.8 0.0094
3 34.7 25.0
EGFR
Positive 45.1 0.8010 47.9 0.4110
Negative 47.6 44.2 
Microvessel count 
<95 37.0 0.0264 43.9 0.1708
≥95 70.9 59.4
Ki-67 labeling index
<15% 50.4 0.5298 46.9 0.3927
≥15% 63.6 62.6
Table 3. Univariate analysis of prognositc factors
*DFS, disease-free survival; OS, overall survival. 
� 1, well differentiated;
2, moderately differentiated; 3, poorly differentiated.
Fig. 2. Disease-free survival (DFS) curve (A) and overall survival (OS) curve (B) according to EGFR expression.
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A BNSCLCs (4-8). In agreement with previous findings (11, 20-
22), we also found that EGFR expression was more frequent
in squamous cell carcinomas than in other histological types
of NSCLCs (35% vs. 23%), although the difference was not
statistically significant (p-value 0.308). Theoretically, high
EGFR expression in squamous cell carcinomas is expected
because EGF promotes the proliferation and differentiation
of epidermal-like tissues. Our series of NSCLC included a rel-
atively small population of squamous cell carcinomas (26/65,
38%), which may have affected our low EGFR expression rate.
EGFR expression is generally low in normal bronchial epi-
thelium, whereas it is enhanced in preneoplastic and neoplastic
bronchial lesions (23). Attempts to establish a relationship
between EGFR expression and other clinical and pathologi-
cal prognostic parameters or prognosis in primary lung cancers,
however, have led to conflicting results. One report showed
no correlation between EGFR expression and pathological
stage, nodal status, or tumor size, although EGFR concentra-
tions were higher in neoplastic than in normal tissues (24).
A second report found that although EGFR expression was
the highest in squamous cell carcinomas, it could not be corre-
lated with other clinicopathological characteristics such as his-
tologic grade or stage (25). In contrast, other investigators have
reported significant correlations between EGFR expression and
more aggressive tumor features, such as tumor stage (22) or
nodal metastases (20). 
In our study, no significant correlations were found between
EGFR expression and several clinicopathological or biologi-
cal parameters, including tumor size, nodal metastasis, his-
tologic grade, and tumor angiogenesis. There was a correla-
tion, however, between EGFR expression and tumor cell pro-
liferative activity, as measured with the Ki-67 proliferation
index. This index measures the proportion of cycling cells and
is a potent biological marker for quantitative estimation of
the growth of neoplasms (26). Binding of EGF or other lig-
ands to EGFR is believed to trigger a series of complex sig-
naling pathways leading to DNA synthesis and cell growth
(27). Thus, our data also suggest that the proliferative activ-
ity of NSCLC may be dependent on EGFR expression. 
In this study, EGFR expression had no significant impact
on DFS or OS in curatively resected stage II or IIIA NSCLC.
EGFR has been reported to act as a strong prognostic marker
in head and neck cancers (28), genito-urinary carcinomas (29,
30) and esophageal cancers (31). In NSCLC, however, findings
have been more ambiguous. Some previous studies have re-
ported that survival rates of patients with high EGF or TGF-
levels were significantly low only in EGFR-positive tumors
(32, 33). In a recent study, 5-yr survival rate of EGFR positive
tumors evaluated by immunohistochemistry (IHC) was sig-
nificantly lower than EGFR negative ones (34). However, sev-
eral studies using specimens from larger numbers of patients
suggested that EGFR expression was not associated with poor
outcome (17, 20, 35). These conflicting data on the relation-
ship between EGFR expression and survival in NSCLC may
be due to heterogeneity of study populations or lack of a stan-
dardized assay for determining EGFR status. More recently,
the first report of EGFR gene copy number in NSCLC using
fluorescence in situ hybridization (FISH) technology showed
that there was no difference in survival between the two FISH
groups (low and high copy numbers of the EGFR gene) (36).
However, high gene copy numbers combined with low level
of EGFR protein expression by IHC had a trend toward poor
prognosis. Because our study was retrospective and analyzed
a relatively small number of tumors, we could not definitely
determine the relationship between EGFR expression and
long-term prognosis. When combined with previous results,
our findings suggest that EGFR may be more important for
lung tumor formation than for tumor progression. The pos-
sibility that EGFR expression plays a prognostic role in pri-
mary NSCLC should be further investigated.
Although EGFR expression may not be useful as a prognos-
tic factor, it has potential clinical implications. The past few
years have seen the rapid development of the EGFR inhibitors,
and an increasing body of evidence suggests that selective
inhibitors of EGFR are potential therapeutic agents for the
treatment of NSCLC in adjuvant, metastatic and chemopre-
ventive settings (37). 
In conclusion, our data show no significant correlations
between EGFR expression in NSCLC and other clinicopatho-
logical parameters such as tumor size, nodal metastasis, angio-
genesis and prognosis. EGFR may be a useful indicator of
tumor cell proliferation in stage II or IIIA NSCLC. Our results
suggest the need for additional prospective studies in patients
with NSCLC.
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